<DOC>
	<DOCNO>NCT00693602</DOCNO>
	<brief_summary>This compassionate use protocol patient acute lymphoblastic leukemia ( ALL ) develop hypersensitivity intolerance E. coli L-asparaginase and/or PEG-L-asparaginase .</brief_summary>
	<brief_title>Compassionate Use Erwinase For Pediatric Patients With Acute Lymphoblastic Leukemia Or Non Hodgkins Lymphoma</brief_title>
	<detailed_description>Primary Objective To provide Erwinase patient acute lymphoblastic leukemia ( ALL ) non-Hodgkins lymphoma intolerant develop hypersensitivity E. coli asparaginase and/or PEG-asparaginase . TREATMENT PLAN Erwinia L-asparaginase administration give accord protocol non-protocol treatment plan patient currently treat . Erwinase discontinue patient experience allergic reaction Grade 3 high adverse event believe attributable agent .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<criteria>Patients treatment acute lymphoblastic leukemia nonHodgkins lymphoma receive ALLtype therapy develop hypersensitivity intolerance E. coli Lasparaginase PEGLasparaginase . Informed consent explain signed parent/legal guardian , emphasis although approve use Europe Canada , Erwinase NOT approve United States Food Drug Administration Documented history severe hypersensitivity intolerance Erwinase</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>